Results 181 to 190 of about 83,183 (296)

Polymorphic myopathological findings in a 77‐year‐old woman with oculo‐bulbo‐facial and distal weakness

Brain Pathology, EarlyView.
Michele Tosi, Angela Puma, Elena Faedo, Gianmarco Severa, Luisa Villa, Sabrina Sacconi, Edoardo Malfatti   +6 more
wiley   +1 more source

Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression

The FEBS Journal, EarlyView.
Here, we report the role of extracellular vesicles (EVs) released from melanoma cells constitutively expressing MHC class II in the regulation of immune cell functions and melanoma metastasis. In particular, we observed an increased localization of HLA‐DRα, CAM receptors, PD‐L1, and STAT3 signaling proteins in the EVs.
Francesca Costantini, Caterina Di Sano, Samuele Raccosta, Mauro Manno, Giovanna Barbieri   +4 more
wiley   +1 more source

AlloPipe and Its Web Server Allogenomics: From Genomic Data to Candidate Minor Histocompatibility Antigens. [PDF]

HLA
Dhuyser A, Delaugère P, Laville P, Clerc R, Aarnink A, Mesnard L, Richard H.   +6 more
europepmc   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

The FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin, Sumit Bhutada, Suneel S. Apte   +2 more
wiley   +1 more source

Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death. [PDF]

Mol Ther Oncol
Chen X, Chen Y, Ping Y.
europepmc   +1 more source

Terasaki's seminal contributions in HLA and Organ Transplantation [PDF]

, 1999
Starzl, TE
core  

TNF‑α Gene Polymorphisms as Determinants of Alloantibody Emergence in Hemophilia: A Systematic Review and Meta‐Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Inhibitor development remains one of the most serious complications of replacement therapy in patients with hemophilia. Tumour necrosis factor‐alpha (TNF‐α) is a key pro‐inflammatory cytokine, and its genetic variants have been implicated in immune‐related conditions.
Alessandra Faustino da Conceição Bezerra, Natã Abner Andrade Carito de Sousa, Suely Meireles Rezende, Renan Pedra de Souza   +3 more
wiley   +1 more source

Editorial: Genetic and immunological insights into angioedema without wheals. [PDF]

Front Immunol
Rijavec M, Margaglione M, Germenis AE.
europepmc   +1 more source

Gene Editing for Haemophilia—The Next Frontier

Haemophilia, EarlyView.
ABSTRACT The recently approved haemophilia A and B gene therapies via adeno‐associated virus (AAV) showed a promising therapeutic response after a single injection, but there are still limitations, including the potential loss of transgene expression and restriction in adults.
Mirko Pinotti, Gregory A. Newby, Sundar Selvaraj, Steven W. Pipe   +3 more
wiley   +1 more source

Cytosolic delivery of bacterial metabolites by riboflavin transporters promotes MR1 antigen presentation and MAIT cell recognition

Immunology &Cell Biology, EarlyView.
VitBAg antigen presentation is promoted through a cytosolic pathway that reaches ligand‐receptive MR1 to present to MAIT cells, like the riboflavin transport pathway. Riboflavin solute carrier transporters can promote this MR1 presentation, but they are not essential for this role, suggesting redundant pathways to uptake VitBAg.
Sebastian Cruz‐Gomez, Hui Jing Lim, Brunda Nijagal, Yuting Yang, Nicole Lau, Jeffrey YW Mak, David P Fairlie, Hayley Newton, Mariolina Salio, Jose A Villadangos, Hamish EG McWilliam   +10 more
wiley   +1 more source